The company, nanoDERM Sciences, Inc. (nDS), is an early stage therapeutic products developer and Institute for Life Science Entrepreneurship (ILSE) member with laboratories in Union, NJ. The company, founder and CEO, Roy Yeoman, leads the nDS R&D team which is dedicated to the discovery, research, development, and commercialization of innovative drug delivery, advanced wound healing, and infectious disease therapy products. The firm's focus is on a nanotechnology platform for drug delivery to address drug-resistent bacteria. The firm's goal is to produce antibacterial nanomedicine to combat Burn Wound Sepsis, the most common and serious complication of major burn injury, accounting for over 60% of deaths in burn patients today.
